April 28, 2020 / 11:54 AM / a month ago

BRIEF-Moleculin Approved To Accelerate European Clinical Trial

April 28 (Reuters) - Moleculin Biotech Inc:

* MOLECULIN APPROVED TO ACCELERATE EUROPEAN CLINICAL TRIAL

* AUTHORIZED BY POLISH DEPARTMENT OF REGISTRATION OF MEDICINAL PRODUCTS TO ACCELERATE PHASE 1 DOSE ESCALATION PORTION OF ITS CLINICAL TRIAL OF ANNAMYCIN FOR TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

* CEO SAYS WE BELIEVE WE CAN AND SHOULD MOVE MORE AGGRESSIVELY TO ESTABLISH MAXIMUM TOLERATED DOSE OF ANNAMYCIN Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below